INAB Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 22:00):

IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers...

Stats
Dagens volum	82 276.00
Gjennomsnittsvolum	341 138
Markedsverdi	43.29M
EPS	$0 ( 2024-04-04 )
Neste inntjeningsdato	( $-0.170 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.000
ATR14	$0.0150 (1.49%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-07	Epperly Corinne	Buy	12 500	Stock Option (right to buy)
2024-02-07	Ho William Tai-wei	Buy	502 000	Employee Stock Option (right to buy)
2024-02-07	Goswami Trishna	Buy	176 000	Employee Stock Option (right to buy)
2024-02-07	Rochlin Kate	Buy	186 000	Employee Stock Option (right to buy)
2024-02-07	Lamb Lawrence	Buy	169 000	Employee Stock Option (right to buy)

INSIDER POWER
24.71
Last 98 transactions
Buy: 9 531 383 \| Sell: 5 834 681

Volum Korrelasjon

Lang: -0.33 (neutral)

Kort: -0.77 (moderate negative)

Signal:(43.529) Neutral

IN8bio, Inc. Korrelasjon

10 Mest positive korrelasjoner
PCVX	0.832
DTSS	0.822
IMPL	0.82
WHLR	0.819
SLM	0.816
AFYA	0.815
JAZZ	0.814
PDSB	0.811
AVIR	0.811
LIVN	0.806

10 Mest negative korrelasjoner
PAE	-0.843
RAVN	-0.832
NEO	-0.828
ZGNX	-0.813
SERA	-0.813
PEGA	-0.81
ACVA	-0.81
EBAC	-0.809
ICON	-0.808
TA	-0.807

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

IN8bio, Inc. Korrelasjon - Valuta/Råvare

0.12
( neutral )

0.59
( weak )

0.00
( neutral )

-0.60
( weak negative )

IN8bio, Inc. Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$-2.50M (0.00 %)
EPS:	$-1.000

FY	2023
Omsetning:	$0
Bruttogevinst:	$-2.50M (0.00 %)
EPS:	$-1.000

FY	2022
Omsetning:	$0
Bruttogevinst:	$-1.10M (0.00 %)
EPS:	$-1.310

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-1.095

Financial Reports:

No articles found.

IN8bio, Inc.

IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Sanntidsoppdatering for IN8bio, Inc. [INAB]

Upcoming Earnings Alert